多西紫杉醇联合顺铂治疗晚期非小细胞肺癌

Effect of docetaxel combined cisplatin for treatment of non small - cell lung cancer

目的观察多西紫杉醇联合顺铂治疗Ⅲ～Ⅳ期非小细胞肺癌（NSCLC）的临床疗效及不良反应。方法32例NSCLC患者采用多西紫杉醇35mg／m^2静脉点滴1h，第1、8天；顺铂（DDP）25mg／m^2静脉点滴，第1、2、3天，化疗前30min给予格拉司琼3mg静注止吐。28d为1个周期，每例患者至少化疗2个周期后进行影像学复查及肿瘤病灶测量，评定疗效及不良反应。结果32例均可评价疗效，完全缓解2例、部分缓解11例，总有效率40．63％（13／32），其中Ⅲ期有效率为45．80％（11／24）；Ⅳ期有效率25．00％（2／8）；中位生存期（MST）为7、5个月，1年生存率为65．63％，主要不良反应为骨髓抑制。结论多西紫杉醇联合顺铂治疗晚期非小细胞肺癌疗效较好，不良反应轻，患者耐受性良好，可作为Ⅲ～Ⅳ期NSCLC的安全有效治疗方案。

Objective To observe the clinical efficacy and adverse effects of combination chemotherapy with docetaxel combined cisplatin in the treatment of m -iv stage non simall -cell lung cancer （NSCLC）. Methods Thirty -two patients with Ⅲ - Ⅳstage NSCLC were enrolled into this study and given treatment of docetaxel combined cisplatin 35 mg/m^2 of docetaxel was injected within one hour in the first and eighth day combined with injection of 25 mg/m^2 cisplatin in first 3 days. 3 mg of granisetron were injected to prevent vomiting before combination chemotherapy. At least 2 courses were conducted with an interval of 28 days. Imageological examination was done and the diameters of tumor were measured to evaluate the effect of treatment and adversd effects. Results The total responsive rate was 40.63% （ 13/32）, 2 of which were cure recovery（CR） and 11 were partial recovery （PR）. responsive rate was 45.80% （ 11/24）in patients with m stage NSCLC and 25.00% （2/8） in patients with Ⅳ stage NSCLC respectively. The median survival time was 7.5 months. The one year survive rate was 65.63%. The main adverse effect was bone marrow depression. Conclusion Combination chemotherapy with docetaxel combined cisplatin in the treatment of m - iv stage NSCLC has good clinical efficacy, light adverse effects and better tolerance, may be an effective and safe treatment for NSCLC.